Literature DB >> 34599402

Identification of novel metabolic signatures potentially involved in the pathogenesis of COPD associated pulmonary hypertension.

Priyanka Choudhury1, Anindita Bhattacharya1, Sanjukta Dasgupta1, Nilanjana Ghosh1, Sayoni Senpupta2, Mamata Joshi3, Parthasarathi Bhattacharyya2, Koel Chaudhury4.   

Abstract

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) associated pulmonary hypertension (COPD-PH), one of the most prevalent forms of PH, is a major burden on the healthcare system. Although PH in COPD is usually of mild-to-moderate severity, its presence is associated with shorter survival, more frequent exacerbations and worse clinical outcomes. The pathophysiologic mechanisms responsible for PH development in COPD patients remain unclear. It is envisioned that a better understanding of the underlying mechanism will help in diagnosis and future treatment strategies.
OBJECTIVES: The present study aims to determine metabolomic alterations in COPD-PH patients as compared to healthy controls. Additionally, to ensure that the dysregulated metabolites arise due to the presence of PH per se, an independent COPD cohort is included for comparison purposes.
METHODS: Paired serum and exhaled breath condensate (EBC) samples were collected from male patients with COPD-PH (n = 60) in accordance with the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines. Age, sex and BMI matched healthy controls (n = 57) and COPD patients (n = 59) were recruited for comparison purposes. All samples were characterized using 1H nuclear magnetic resonance (NMR) spectroscopy.
RESULTS: Fifteen serum and 9 EBC metabolites were found to be significantly altered in COPD-PH patients as compared to healthy controls. Lactate and pyruvate were dysregulated in both the biofluids and were further correlated with echocardiographic systolic pulmonary artery pressure (sPAP). Multivariate analysis showed distinct class separation between COPD-PH and COPD.
CONCLUSIONS: The findings of this study indicate an increased energy demand in patients with COPD-PH. Furthermore, both lactate and pyruvate correlate with sPAP, indicating their importance in the clinical course of the disease.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  COPD; EBC; Metabolomics; NMR; Pulmonary hypertension; Serum

Mesh:

Substances:

Year:  2021        PMID: 34599402     DOI: 10.1007/s11306-021-01845-9

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  35 in total

1.  Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies.

Authors:  Olivier Cloarec; Marc E Dumas; Johan Trygg; Andrew Craig; Richard H Barton; John C Lindon; Jeremy K Nicholson; Elaine Holmes
Journal:  Anal Chem       Date:  2005-01-15       Impact factor: 6.986

2.  Separating smoking-related diseases using NMR-based metabolomics of exhaled breath condensate.

Authors:  Guglielmo de Laurentiis; Debora Paris; Dominique Melck; Paolo Montuschi; Mauro Maniscalco; Andrea Bianco; Matteo Sofia; Andrea Motta
Journal:  J Proteome Res       Date:  2013-02-12       Impact factor: 4.466

3.  1H NMR To Explore the Metabolome of Exhaled Breath Condensate in α1-Antitrypsin Deficient Patients: A Pilot Study.

Authors:  Cristina Airoldi; Carlotta Ciaramelli; Marco Fumagalli; Rita Bussei; Valeria Mazzoni; Simona Viglio; Paolo Iadarola; Jan Stolk
Journal:  J Proteome Res       Date:  2016-10-05       Impact factor: 4.466

Review 4.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

5.  Metabolomics reveals metabolite changes in acute pulmonary embolism.

Authors:  Renata Bujak; Ana García-Álvarez; Francisco J Rupérez; Mario Nuño-Ayala; Antonia García; Jesus Ruiz-Cabello; Valentín Fuster; Borja Ibáñez; Coral Barbas
Journal:  J Proteome Res       Date:  2014-01-08       Impact factor: 4.466

6.  New Biochemical Insights into the Mechanisms of Pulmonary Arterial Hypertension in Humans.

Authors:  Renata Bujak; Jesús Mateo; Isabel Blanco; José Luis Izquierdo-García; Danuta Dudzik; Michał J Markuszewski; Victor Ivo Peinado; Martín Laclaustra; Joan Albert Barberá; Coral Barbas; Jesús Ruiz-Cabello
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

Review 7.  Updated Perspectives on Pulmonary Hypertension in COPD.

Authors:  Isabel Blanco; Olga Tura-Ceide; Victor Ivo Peinado; Joan Albert Barberà
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-06-09

8.  Individual free fatty acids have unique associations with inflammatory biomarkers, insulin resistance and insulin secretion in healthy and gestational diabetic pregnant women.

Authors:  Xinhua Chen; T Peter Stein; Robert A Steer; Theresa O Scholl
Journal:  BMJ Open Diabetes Res Care       Date:  2019-05-16

9.  Metabolomics reveals metabolite changes of patients with pulmonary arterial hypertension in China.

Authors:  Chenyang Chen; Fei Luo; Panyun Wu; Yiyuan Huang; Avash Das; Shenglan Chen; Jingyuan Chen; Xinqun Hu; Fei Li; Zhenfei Fang; Shenhua Zhou
Journal:  J Cell Mol Med       Date:  2020-01-16       Impact factor: 5.310

10.  Two chair test: a substitute of 6 min walk test appear cardiopulmonary reserve specific.

Authors:  Parthasarathi Bhattacharyya; Dipanjan Saha; Mintu Paul; Dhiman Ganguly; Biswarup Mukherjee; Sushmita Roy Chowdhury; Sourav RoyChoudhury; Pawan Agarwal; Indranil Halder; Debanu Ghosh Roy; Shuvanan Ray
Journal:  BMJ Open Respir Res       Date:  2020-09
View more
  1 in total

Review 1.  Metabolomic Fingerprinting for the Detection of Early-Stage Lung Cancer: From the Genome to the Metabolome.

Authors:  Jean-François Haince; Philippe Joubert; Horacio Bach; Rashid Ahmed Bux; Paramjit S Tappia; Bram Ramjiawan
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.